ArticleGene therapy2002
Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 117 citations in OpenAlex.
- 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence.International urogynecology journal and pelvic floor dysfunction · 2008Trial
- Cell Therapy in the Treatment of Female Stress Urinary Incontinence: Current Status and Future Proposals.Life (Basel, Switzerland) · 2024Review
- Stem cell therapy combined with controlled release of growth factors for the treatment of sphincter dysfunction.Cell & bioscience · 2023Review
- Exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence.NPJ Regenerative medicine · 2022Article
- Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration.Stem cell research & therapy · 2020Article
- Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative.International neurourology journal · 2020Article
- Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction.Stem cell reviews and reports · 2020Review
- Underactive bladder: A review of the current treatment concepts.Turkish journal of urology · 2019Review
- Harnessing the mesenchymal stem cell secretome for regenerative urology.Nature reviews. Urology · 2019Review
- Recent advances in the understanding and management of underactive bladder.F1000Research · 2018Review
- Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB).International urology and nephrology · 2017Review
- Basal Lamina Mimetic Nanofibrous Peptide Networks for Skeletal Myogenesis.Scientific reports · 2015Article
- A novel method for differentiation of human mesenchymal stem cells into smooth muscle-like cells on clinically deliverable thermally induced phase separation microspheres.Tissue engineering. Part C, Methods · 2015Article
- Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study.International urology and nephrology · 2015Article
- Advanced therapeutic directions to treat the underactive bladder.International urology and nephrology · 2014Review
- Dynamics of acute local inflammatory response after autologous transplantation of muscle-derived cells into the skeletal muscle.Mediators of inflammation · 2014Article
- Stem cell therapy in bladder dysfunction: where are we? And where do we have to go?BioMed research international · 2013Review
- The other bladder syndrome: underactive bladder.Reviews in urology · 2013Article
- Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysis.Neural regeneration research · 2012Article
- Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms.Translational andrology and urology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
We have tested the feasibility of muscle-based gene therapy and tissue engineering for urological dysfunction using highly purified muscle-derived cells (MDC) that display stem cell characteristics. We then explored the potential use of these MDC as an alternative therapy for the treatment of impaired detrusor contractility. The MDC were genetically engineered to express the gene encoding beta-galactosidase and injected into the bladder walls of SCID mice. The injected bladders were harvested at various time-points after injection and assayed for beta-galactosidase activity; the presence of myofibers within the injected tissue was determined by detection of fast myosin heavy chain isoform (MyHCs). We have demonstrated that the injected MDC are capable of not only surviving in the lower urinary tract, but also improving the contractility of the bladder following an induced injury. Two potential mechanisms can be used to explain this finding. First, we have observed that some of the beta-galactosidase-expressing cells expressed alpha-smooth muscle actin, suggesting a differentiation into smooth muscle. Second, a stain for acetylcholine receptors (AChRs), which identifies the location of neuromuscular junctions, revealed that the myofibers derived from the doner cells became innervated into the bladder as early as 2 weeks after injection. These results suggest that gene therapy and tissue engineering based on MDC potentially can be used for urological dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.